Premium
Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices ( EILAT XIII )
Author(s) -
Bialer Meir,
Johannessen Svein I.,
Levy René H.,
Perucca Emilio,
Tomson Torbjörn,
White H. Steve
Publication year - 2017
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/epi.13634
Subject(s) - medicine , oxcarbazepine , bumetanide , epilepsy , pharmacology , psychiatry , chemistry , organic chemistry , sodium , cotransporter , carbamazepine
Summary The Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII) took place in Madrid, Spain, on June 26–29, 2016, and was attended by >200 delegates from 31 countries. The present Progress Report provides an update on experimental and clinical results for drugs presented at the Conference. Compounds for which summary data are presented include an AED approved in 2016 (brivaracetam), 12 drugs in phase I– III clinical development (adenosine, allopregnanolone, bumetanide, cannabidiol, cannabidivarin, 2‐deoxy‐ d ‐glucose, everolimus, fenfluramine, huperzine A, minocycline, SAGE ‐217, and valnoctamide) and 6 compounds or classes of compounds for which only preclinical data are available (bumetanide derivatives, sec ‐butylpropylacetamide, FV ‐082, 1 OP ‐2198, NAX 810‐2, and SAGE ‐689). Overall, the results presented at the Conference show that considerable efforts are ongoing into discovery and development of AED s with potentially improved therapeutic profiles compared with existing agents. Many of the drugs discussed in this report show innovative mechanisms of action and many have shown promising results in patients with pharmacoresistant epilepsies, including previously neglected rare and severe epilepsy syndromes.